TGFβ Pathway

How it works

Benefits

Evidence quality

Highlighted claims

• The response to TGFβ blockade is not universal across all genetic subtypes of osteogenesis imperfecta. — Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the ‘MOI-A’ study; a randomised, phase 2/pilot, dose
• A pan-TGFβ neutralising antibody reduced CTX and restored vertebral bone mass and architecture in the severe Crtap-/- mouse model. — Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the ‘MOI-A’ study; a randomised, phase 2/pilot, dose
• TGFβ pathway signalling is increased in osteogenesis imperfecta for unclear reasons. — Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the ‘MOI-A’ study; a randomised, phase 2/pilot, dose
• Multiple model systems support targeting TGFβ signalling as a therapeutic strategy in osteogenesis imperfecta. — Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the ‘MOI-A’ study; a randomised, phase 2/pilot, dose